# PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer

> **NCT04176952** · PHASE2 · TERMINATED · sponsor: **Judith Dixon-Hughes** · enrollment: 31 (actual)

## Conditions studied

- Neoplasms Pancreatic

## Interventions

- **DRUG:** FOLFOX-A
- **DRUG:** AG

## Key facts

- **NCT ID:** NCT04176952
- **Lead sponsor:** Judith Dixon-Hughes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-05
- **Primary completion:** 2021-08-19
- **Final completion:** 2021-08-19
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Due to funding being withdrawn
- **Last updated:** 2022-05-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04176952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04176952, "PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04176952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*